Angiotensin-converting Enzyme Inhibitor or Angiotensin Receptor Blocker Adherence in Patients With Primary Versus Secondary Diagnosis of Heart FailureByMarica L. Brackbill, PharmD,Rebecca Bashaw-Keaton, PharmD,Christine S. Sytsma, RN, MSNOctober 1st 2007
Increasing Pneumococcal Vaccination in Managed Care Through Telephone OutreachByCarla A. Winston, MA, PhD,Adrienne D. Mims, MD, MPH,Kecia A. Leatherwood, MSOctober 1st 2007
Reasons Provided by Prescribers When Overriding Drug-Drug Interaction AlertsByAmy J. Grizzle, PharmD,Maysaa H. Mahmood, MS,Yu Ko, MS,John E. Murphy, PharmD,Edward P. Armstrong, PharmD,Grant H. Skrepnek, PhD,William N. Jones, MS,Gregory P. Schepers, PharmD,W. Paul Nichol, MD,Antoun Houranieh, PhD,Donna C. Dare, PharmD,Christopher T. Hoey, PharmD,Daniel C. Malone, PhDOctober 1st 2007
Angiotensin-converting Enzyme Inhibitor Therapy for Coronary Artery Disease and Diabetes MellitusByKaren J. McConnell, PharmD,Emily B. Zadvorny, PharmD,Anne M. Denham, PharmD,Sheila L. Kasten, PharmD,Kara A. Hutka, PharmD,Cedar R. Koetting, PharmD,John A. Merenich, MD,for the Clinical Pharmacy Cardiac Risk Service Study GroupOctober 1st 2007
Comparison of Administrative-only Versus Administrative Plus Chart Review Data for Reporting HEDIS Hybrid MeasuresByL. Gregory Pawlson, MD,Sarah Hudson Scholle, DrPH,Anne Powers, PhDOctober 1st 2007
The Performance of Performance MeasuresByKaren S. Kmetik, PhD,Jeanette Chung, PhD,Shannon Sims, MD, PhDOctober 1st 2007
